Crestline Management LP raised its stake in shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) by 14.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 68,906 shares of the company’s stock after acquiring an additional 8,442 shares during the period. Crestline Management LP owned approximately 0.26% of Reata Pharmaceuticals worth $1,951,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Nationwide Fund Advisors lifted its stake in Reata Pharmaceuticals by 38.1% during the 2nd quarter. Nationwide Fund Advisors now owns 4,368 shares of the company’s stock valued at $138,000 after acquiring an additional 1,206 shares during the period. Wells Fargo & Company MN lifted its stake in Reata Pharmaceuticals by 37.4% during the 2nd quarter. Wells Fargo & Company MN now owns 5,591 shares of the company’s stock valued at $176,000 after acquiring an additional 1,521 shares during the period. American International Group Inc. lifted its stake in Reata Pharmaceuticals by 42.5% during the 3rd quarter. American International Group Inc. now owns 7,528 shares of the company’s stock valued at $234,000 after acquiring an additional 2,247 shares during the period. Bank of New York Mellon Corp lifted its stake in Reata Pharmaceuticals by 5.5% during the 4th quarter. Bank of New York Mellon Corp now owns 47,164 shares of the company’s stock valued at $1,336,000 after acquiring an additional 2,461 shares during the period. Finally, California State Teachers Retirement System lifted its stake in Reata Pharmaceuticals by 20.8% during the 2nd quarter. California State Teachers Retirement System now owns 15,125 shares of the company’s stock valued at $479,000 after acquiring an additional 2,600 shares during the period. Institutional investors and hedge funds own 49.33% of the company’s stock.
In other Reata Pharmaceuticals news, major shareholder James W. Traweek, Jr. acquired 12,000 shares of the stock in a transaction dated Tuesday, December 26th. The shares were purchased at an average price of $26.06 per share, for a total transaction of $312,720.00. Following the purchase, the insider now directly owns 35 shares of the company’s stock, valued at $912.10. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Cpmg Inc acquired 200,000 shares of the stock in a transaction dated Thursday, December 14th. The stock was acquired at an average price of $24.79 per share, for a total transaction of $4,958,000.00. Following the purchase, the director now directly owns 113 shares in the company, valued at $2,801.27. The disclosure for this purchase can be found here. Insiders bought a total of 288,200 shares of company stock worth $7,331,446 in the last quarter. Company insiders own 44.00% of the company’s stock.
Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings data on Friday, March 2nd. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.08). The firm had revenue of $9.96 million for the quarter, compared to analysts’ expectations of $11.18 million. analysts expect that Reata Pharmaceuticals Inc will post -2.54 EPS for the current fiscal year.
Several equities analysts have issued reports on RETA shares. Cowen restated a “buy” rating on shares of Reata Pharmaceuticals in a research note on Thursday, December 14th. BidaskClub upgraded shares of Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Finally, Zacks Investment Research cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 16th. Three equities research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $54.71.
ILLEGAL ACTIVITY NOTICE: “Reata Pharmaceuticals Inc (RETA) Shares Bought by Crestline Management LP” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/03/14/reata-pharmaceuticals-inc-reta-shares-bought-by-crestline-management-lp.html.
Reata Pharmaceuticals Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.